NaBen®

DRUG3 trials

Sponsors

SyneuRx International (Taiwan) Corp

Conditions

Refractory SchizophreniaSchizophrenia

Phase 2

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

TerminatedNCT01908192

SyneuRx International (Taiwan) CorpSchizophrenia

Start: 2014-06-30End: 2023-10-26Updated: 2024-05-09

Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults

TerminatedNCT02261519

SyneuRx International (Taiwan) CorpSchizophrenia

Start: 2017-03-29End: 2023-11-29Updated: 2024-05-24

An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

RecruitingNCT03094429

SyneuRx International (Taiwan) CorpRefractory Schizophrenia

Start: 2017-03-29End: 2026-12-31Target: 287Updated: 2021-09-13